Janux Therapeutics Inc.

NASDAQ: JANX · Real-Time Price · USD
25.04
0.07 (0.28%)
At close: Aug 15, 2025, 3:59 PM
25.11
0.30%
After-hours: Aug 15, 2025, 04:10 PM EDT

Janux Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
10.59M 8.08M 8.61M 3.64M
Cost of Revenue
2.06M 1.96M 841K 113K
Gross Profit
8.53M 6.13M 7.77M 3.52M
Operating Income
-98.85M -72.98M -67.09M -32.93M
Interest Income
29.85M 14.69M 4.03M 257K
Pretax Income
-68.99M -58.29M -63.06M -32.67M
Net Income
-68.99M -58.29M -63.06M -32.56M
Selling & General & Admin
41.05M 26.14M 22.26M 10.33M
Research & Development
68.39M 54.92M 53.44M 26.24M
Other Expenses
-2.06M -1.96M -841K n/a
Operating Expenses
107.38M 79.11M 74.86M 36.57M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
109.44M 81.06M 75.7M 36.57M
Income Tax Expense
n/a n/a n/a -113K
Shares Outstanding (Basic)
53.75M 44.02M 41.47M 41.24M
Shares Outstanding (Diluted)
53.75M 44.02M 41.47M 41.24M
EPS (Basic)
-1.28 -1.32 -1.52 -0.79
EPS (Diluted)
-1.28 -1.32 -1.52 -0.79
EBITDA
-98.85M -71.02M -66.25M -32.82M
EBIT
-98.85M -72.98M -67.09M -32.93M
Depreciation & Amortization
2.06M 1.96M 841K 113K